Healx AI alliance with US-based Vuja De Sciences targets killer cancer recurrence

Healx is an AI-powered biotech company pioneering the next generation of drug discovery for rare diseases and Vuja De Sciences develops metastasis treatments designed to prevent the recurrence and spread of cancer. No financial details of the partnership are being disclosed.

The Cambridge company's proprietary AI platform has uncovered and prioritised therapeutic opportunities across rare diseases and is actively applied in rare and paediatric oncology. The platform is designed to generate and advance Healx’s own discovery programs, making it a natural fit with Vuja De Sciences, which brings both deep expertise in metastatic recurrence and a clinical-stage programme targeting cancer recurrence in osteosarcoma. These capabilities are highly complementary with Healx’s strategic focus and AI-driven approach.

Together with Healx’s neurofibromatosis type 1 (NF1) program, this transaction reinforces the Cambridge company’s established rare and paediatric oncology focus and further strengthens its growing therapeutic portfolio aimed at delivering innovative treatments for underserved patient communities.

This transaction underscores Healx’s mission-driven use of AI for good - applying cutting-edge technology to accelerate treatment discovery and bring meaningful options to rare disease patients.

By combining Healx’s platform with Vuja De’s innovative program, the companies are advancing a promising therapy, HLX-4310, for preventing recurrence of metastatic osteosarcoma and deepening their shared commitment to rare and pediatric oncology. With the addition of this programme, Healx now advances two clinical-stage assets in this area.

“At Healx, we believe our AI platform can help solve humanity’s toughest health challenges - cancer recurrence,” said Dr. Tim Guilliams, CEO and Co-founder of Healx.

“By joining forces with Vuja De Sciences, we are combining our AI driven discovery capabilities with their science innovation to accelerate novel breakthrough cancer treatments – starting with a promising therapy entering clinical trials this year.”

Healx Chair Dr. Jonathan Milner added: “This is a pivotal moment for Healx. By bringing together world-class science and cutting-edge AI, we are creating new opportunities to reshape the future of rare and paediatric cancers. I’m inspired by the path ahead and the impact we can make for patients”

Dr. David Warshawsky, Founder & CEO of Vuja De Sciences, will continue to lead the osteosarcoma program and will be joining the Healx executive team as Global Head of Metastatic Prevention. He said: “We are delighted to join forces with Healx and share a deep commitment to addressing rare diseases. Metastatic osteosarcoma is a devastating cancer affecting mostly young patients, with a five-year survival rate of less than 20 per cent.

“Our innovative therapeutic strategy aims to prevent recurrence and transform outcomes. Pairing our science with Healx’s AI platform broadens our reach and accelerates our mission to change the trajectory of rare cancers.”

The FDA has cleared the Investigational New Drug (IND) application for HLX-4310, demonstrating readiness to advance into clinical trials. The venture is progressing with the National Pediatric Cancer Foundation’s flagship research program – the Sunshine Project™ – for the upcoming Phase 1/2 clinical trial.